Earnings summaries and quarterly performance for NASDAQ.
Executive leadership at NASDAQ.
Adena Friedman
Detailed
Chair and Chief Executive Officer
CEO
BP
Bradley Peterson
Detailed
Executive Vice President and Chief Information Officer/Chief Technology Officer
BS
Bryan Smith
Detailed
Executive Vice President and Chief People Officer
JS
Jeremy Skule
Detailed
Executive Vice President and Chief Strategy Officer; Executive Chair, Financial Crime Management Technology
JZ
John Zecca
Detailed
Executive Vice President and Chief Legal, Risk and Regulatory Officer
MD
Michelle Daly
Detailed
Senior Vice President and Controller and Principal Accounting Officer
NG
Nelson Griggs
Detailed
President
SY
Sarah Youngwood
Detailed
Executive Vice President and Chief Financial Officer
TC
Tal Cohen
Detailed
President
Board of directors at NASDAQ.
AZ
Alfred Zollar
Detailed
Director
CB
Charlene Begley
Detailed
Director
EK
Essa Kazim
Detailed
Director
HS
Holden Spaht
Detailed
Director
JY
Jeffery Yabuki
Detailed
Director
JT
Johan Torgeby
Detailed
Director
KK
Kathryn Koch
Detailed
Director
MA
Melissa Arnoldi
Detailed
Director
MS
Michael Splinter
Detailed
Lead Independent Director
TK
Thomas Kloet
Detailed
Director
TT
Toni Townes-Whitley
Detailed
Director
Research analysts who have asked questions during NASDAQ earnings calls.
Alexander Blostein
Goldman Sachs
8 questions for NDAQ
Also covers: AB, AMG, AMP +31 more
Brian Bedell
Deutsche Bank
7 questions for NDAQ
Also covers: AMG, AMTD, APO +24 more
Michael Cyprys
Morgan Stanley
7 questions for NDAQ
Also covers: AAMI, AMP, AMTD +30 more
Ashish Sabadra
RBC Capital Markets
6 questions for NDAQ
Also covers: ADP, CBOE, CLVT +20 more
Benjamin Budish
Barclays PLC
6 questions for NDAQ
Also covers: AB, APO, ARES +24 more
OL
Owen Lau
Oppenheimer & Co. Inc.
6 questions for NDAQ
Also covers: BLSH, CLVT, CME +9 more
PM
Patrick Moley
Piper Sandler & Co.
6 questions for NDAQ
Also covers: BGC, CBOE, CME +17 more
AK
Alex Kramm
UBS Group AG
5 questions for NDAQ
Also covers: BR, CBOE, CBRE +16 more
DF
Dan Fannon
Jefferies & Company Inc.
5 questions for NDAQ
Also covers: AB, AMG, AMTD +26 more
JS
Jeff Schmitt
William Blair & Company, L.L.C.
5 questions for NDAQ
Also covers: AIZ, AMP, CBOE +11 more
MC
Michael Cho
JPMorgan Chase & Co.
5 questions for NDAQ
Also covers: ENV, FHI, FRGE +4 more
EA
Eli Abboud
Bank of America
4 questions for NDAQ
Also covers: BGC, CBOE, CME +2 more
SC
Simon Clinch
Redburn Atlantic
4 questions for NDAQ
Also covers: CME, EFX, FICO +4 more
Craig Siegenthaler
Bank of America
3 questions for NDAQ
Also covers: AB, AMP, AMTD +26 more
DF
Daniel Fannon
Jefferies Financial Group Inc.
3 questions for NDAQ
Also covers: AB, AMG, AMTD +28 more
Kyle Voigt
Keefe, Bruyette & Woods
3 questions for NDAQ
Also covers: AMTD, APO, ARES +17 more
AK
Alexander Kramm
UBS Group AG
2 questions for NDAQ
WK
William Katz
TD Cowen
2 questions for NDAQ
Also covers: AB, AMG, AMTD +25 more
YC
Y. Cho
JPMorgan Chase & Co.
2 questions for NDAQ
Also covers: LPLA
Ben Budish
Barclays PLC
1 question for NDAQ
Also covers: AB, APO, ARES +23 more
Brian Bertram Bedell
Deutsche Bank AG
1 question for NDAQ
CA
Christopher Allen
Citigroup
1 question for NDAQ
Also covers: CBOE, CME, ETOR +9 more
JS
Jeffrey Schmitt
William Blair
1 question for NDAQ
Also covers: AIZ, AMP, CBOE +8 more
KS
Kwun Sum Lau
Oppenheimer
1 question for NDAQ
Also covers: CBOE, CLVT, CME +9 more
SA
Simon Alistair Clinch
Redburn Atlantic
1 question for NDAQ
Also covers: CME, EFX, FICO +3 more
Recent press releases and 8-K filings for NDAQ.
NASDAQ receives FDA approval for once-weekly YUVIWEL
NDAQ
Product Launch
- The FDA granted accelerated approval for YUVIWEL® (navepegritide) as the first once-weekly treatment to increase linear growth in children aged 2 years and older with achondroplasia, based on improved annualized growth velocity.
- YUVIWEL is designed to provide continuous systemic exposure to C-type natriuretic peptide (CNP) over the weekly dosing interval to counteract overactive FGFR3 signaling.
- Commercial availability is expected in the early part of Q2 2026, supported by Ascendis’s U.S. Signature Access Program offering patient journey and financial assistance services.
- The FDA also issued a Rare Pediatric Disease Priority Review Voucher, granting priority review for a subsequent drug application.
2 hours ago
SEGG Media acquires majority stake in Veloce Media Group
NDAQ
M&A
- SEGG Media acquired a controlling supermajority interest in Veloce Media Group for $61 million, expanding its international footprint and scaling its top line.
- Veloce’s five-pillar revenue model spans digital advertising, creator representation, esports/sim racing services, sustainable motorsport, and direct-to-consumer commerce via Quadrant.
- In 2025, Veloce posted $2.17 million in digital advertising and its esports/sim racing division earned $3.36 million, while Quadrant’s H2 2025 partnerships revenue reached $2.45 million alongside $675,000 in merchandise sales.
- Management projects that Veloce and Quadrant will generate over $20 million in revenue in 2026.
8 hours ago
New Era Energy & Digital announces 450 MW behind-the-meter generation at TCDC
NDAQ
New Projects/Investments
- New Era Energy & Digital will deploy 450 MW of behind-the-meter generation capacity at its Texas Critical Data Center (TCDC) in partnership with Thunderhead Energy and Turbine-X Energy.
- The arrangement secures key power equipment and advances procurement to keep the project on its anticipated development and construction schedule.
- The plan aligns with the Trump Administration’s Ratepayer Protection Pledge to protect the public grid and promote private power solutions for large-scale data centers.
- TCDC is a 438-acre AI and high-performance computing campus in Ector County, Texas, master-planned to scale to 1+ gigawatt of capacity, offering turnkey digital infrastructure and integrated power assets.
11 hours ago
FullPAC outlines strategic expansion ahead of 2026 Midterms
NDAQ
M&A
Delisting/Listing Issues
- FullPAC, a nonpartisan campaign technology provider for over 5,000 clients, highlights its role in powering high-volume communications ahead of the 2026 Midterm Elections.
- The 2026 election cycle is projected to reach $10.8 billion in advertising spend, a 20% increase over the 2022 midterms.
- In October 2025 and January 2026, FullPAC acquired Advocacy Lab (AI content generation) and Govt.com (constituent outreach), expanding its service offerings and recurring revenue base.
- The Company’s platform also supports corporate proxy communications for Nasdaq- and NYSE-listed issuers, and it has reserved the “GOTV” ticker for a planned Nasdaq Capital Market listing via a Reg A+ offering, targeting $15 million in market value of unrestricted securities.
12 hours ago
ProCap Financial repurchases shares at 25% discount to NAV
NDAQ
Share Buyback
- ProCap Financial repurchased 159,904 shares on February 26, 2026 at approximately 25% discount to Net Asset Value (NAV).
- The firm is pursuing aggressive share repurchases to narrow its NAV discount, according to CEO Anthony Pompliano.
- Founded in 2025 with over $750 million raised, ProCap Financial trades on Nasdaq under the ticker BRR.
13 hours ago
New Era Energy & Digital secures LOI for 54-acre corridor at TCDC
NDAQ
New Projects/Investments
- New Era entered a non-binding LOI to acquire 54 acres adjacent to its 438-acre Texas Critical Data Centers campus in Ector County, Texas, supporting ongoing lease talks with a hyperscale tenant.
- The acquisition will enhance the campus—master-planned to scale to 1+ gigawatt—by optimizing power interconnection design and enabling direct power offtake arrangements.
- Ongoing site work includes land clearing, removal and relocation of pipeline infrastructure, and subsurface soil sampling to support civil engineering design.
- Management expects the corridor to boost negotiating leverage with power producers, reduce grid congestion risk, and improve redundancy and reliability for high-performance computing tenants.
1 day ago
ProCap Financial accelerates share buybacks at 28% NAV discount
NDAQ
Share Buyback
- ProCap repurchased 159,904 shares at an approximate 28% discount to NAV on February 25, 2026.
- NAV stands at ~$316 million, with 82,800,271 basic shares outstanding, implying a NAV per share of ~$3.82 and a current discount of ~28%.
- CEO Anthony Pompliano reaffirmed commitment to ongoing buybacks, stating every purchase is accretive and will continue if the discount persists.
1 day ago
Crescent Biopharma reports Q4 and full-year 2025 financial results and partnership expansion
NDAQ
Earnings
New Projects/Investments
- Reported $10.8 million revenue in 2025 vs. none in 2024, a full-year net loss of $153.9 million (Q4 loss $92.4 million), R&D expenses of $138.1 million, and held $213.2 million cash as of Dec. 31, 2025, funding operations into 2028.
- Completed a $185 million private placement in December 2025 to support key clinical readouts beginning Q1 2027.
- Announced a strategic partnership with Sichuan Kelun-Biotech granting Crescent rights to CR-003 outside Greater China and Kelun-Biotech rights to CR-001 in Greater China.
- Advanced pipeline: FDA cleared the IND for CR-001, first patient dosed in the Phase 1/2 ASCEND trial, with first ADC combination trial expected H2 2026.
1 day ago
N2OFF announces rebranding to Nexentis Technologies
NDAQ
M&A
New Projects/Investments
- N2OFF will rebrand as Nexentis Technologies Inc. and change its Nasdaq ticker to NXTS effective February 26, 2026.
- On October 20, 2025, N2OFF completed the acquisition of MitoCareX Bio Ltd, marking a strategic pivot from cleantech to biotech and making MitoCareX a wholly owned subsidiary.
- The company plans to leverage the MITOLINE™ computational platform for mitochondrial carrier biology across precision oncology and inflammatory metabolic diseases, while continuing to manage its non-core solar energy investments.
- Early in vitro results from MITOLINE-powered discovery rounds have shown anti-tumor activity and reduced pro-inflammatory markers, supporting further preclinical lead optimization.
3 days ago
Eagle Nuclear Energy Corp. commences trading on Nasdaq
NDAQ
Delisting/Listing Issues
- Eagle Nuclear Energy Corp. commenced trading on the Nasdaq under the ticker symbols NUCL and NUCLW.
- It is the first U.S. domestic uranium exploration company with exclusive small modular reactor (SMR) technology to list on a U.S. exchange.
- The company’s flagship Aurora Uranium Project hosts the largest conventional, measured and indicated uranium deposit in the U.S., with 32.75 million pounds indicated and 4.98 million pounds inferred of near-surface uranium.
3 days ago
Fintool News
In-depth analysis and coverage of NASDAQ.
Quarterly earnings call transcripts for NASDAQ.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more